Virbac has a very strong presence in the large animal health segment in several Regions (Asia Pacific, Europe and Latin America). This will be Virbac's first foray into this segment for the U.S. market.

Pharmgate has a strong position in Swine, a heavily consolidated segment of the market. Pharmgate will represent Virbac to swine veterinarians and producers and work closely on Virbac's behalf. They have a very robust sales and technical services division and are a natural fit with Virbac.

"We are excited to partner with a reputable Animal Health supplier as they launch a range of products into the large animal market" says Ed Seed, Head of Global Sales & Marketing for Pharmgate. "Adding these quality products to our portfolio over the coming year will expand our product offering in fulfilling our customers' complete therapeutic product needs".

"We see Pharmgate, with its broad portfolio of products, strong field team and focus on swine as being in a unique position to support Virbac as we enter the US swine industry,'' says Francois Fournier, President & CEO, North America. "With the swine industry being highly concentrated, we need a company that has key relationships and expertise and Pharmgate felt like the perfect fit".

Attachments

  • Original document
  • Permalink

Disclaimer

Virbac SA published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2021 16:01:05 UTC.